ZNF224 and B-cell chronic lymphocytic leukemia: The evaluation of ZNF224 expression levels, combined with established clinical and molecular markers, could contribute to more accurate risk stratification in CLL patients and provide an effective method for early monitoring of adverse events during therapy.